Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer plans to charge COVID patients around $1,400 for a five-day course of the antiviral drug Paxlovid — nearly triple the amount the US government paid during the coronavirus pandemic ...

Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Pfizer had previously estimated sales of Paxlovid on the year to only reach $8 billion, as demand for Covid vaccines and treatment wanes and the World Health Organization said the pandemic is ...

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can ...

Pfizer stands to make a huge amount of money from Paxlovid. The investment bank SVB Leerink estimated that the drug would bring in $24 billion in global revenue in 2022 and $33 billion in 2023.

Pfizer announced on Thursday it has reached an agreement to supply up to six million courses of its COVID-19 antiviral Paxlovid to the Global Fund to get treatment to low and middle-income ...

When given within five days of the onset of symptoms, the antiviral therapy, called Paxlovid, prevented almost 90% of deaths from COVID-19 compared with a placebo, a Pfizer study found.